METHOFRACT:甲氨蝶呤骨病多中心队列研究
该多中心回顾性研究纳入2012至2024年间92例甲氨蝶呤诱导骨病(MTX-IO)患者,多为血清阳性类风湿关节炎绝经后女性。骨折最常见于胫骨骨干骺端(88%)和足骨(49%),76%诊断时存在多发骨折。停用甲氨蝶呤者骨折愈合及疼痛缓解率91%,继续用药者29%(p<0.001)。
要点
- MTX-IO多见于控制良好的RA或PsA绝经后女性,常见胫骨或足骨骨折。
- 诊断时76%存在多发骨折,63%近期有反复骨折史。
- 停用甲氨蝶呤者骨折愈合及疼痛缓解率91%,继续用药者29%(p<0.001)。
核心结论
- MTX-IO是一种罕见但重要的疾病,尤其见于RA或PsA绝经后女性。
- 通过MRI或骨闪烁显像早期诊断并停用甲氨蝶呤至关重要,停药可显著改善结局并预防进一步骨折。
研究设计与样本
- 多中心回顾性研究,纳入2012至2024年间由骨专科医生诊断或经法国药物警戒系统识别的MTX-IO患者,共92例。
主要发现
- 92例患者以血清阳性RA绝经后女性为主,22%有重大骨折史,56%诊断时存在骨质疏松。
- 骨折最常见于胫骨骨干骺端(远端和近端)(88%)和足骨(49%),76%诊断时存在多发骨折,63%近期有反复骨折史。
- 诊断采用疼痛部位MRI者占84%,采用骨闪烁显像者41例(45%)。
- 79%的病例停用了甲氨蝶呤;77%的病例实现骨折愈合和疼痛缓解。
- 停用甲氨蝶呤者骨折愈合及疼痛缓解率为91%,继续用药者为29%(p<0.001)。
临床怎么用
- 作者认为,通过MRI或骨闪烁显像早期诊断并停用甲氨蝶呤至关重要,停药可显著改善结局并预防进一步骨折。
- 研究中79%的病例停用了甲氨蝶呤。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Methotrexate-induced osteopathy (MTX-IO) is a rare condition typically involving the lower limbs, especially tibia or foot fractures, among patients with well-controlled rheumatoid arthritis (RA) or psoriatic arthritis (PsA). This study aimed to identify the affected population, describe fracture characteristics and identify risk factors for poor clinical outcome. A multicentre retrospective study included patients with MTX-IO diagnosed by bone specialists or identified through French pharmacovigilance. The data collected included clinical presentation, imaging features, bone mineral density and biochemical markers. Between 2012 and 2024, 92 patients were included, predominantly postmenopausal women with seropositive RA. A history of major fractures was noted for 22% of the patients, and 56% presented osteoporosis at diagnosis. Fractures were most common in the tibial metaphysis (distal and proximal) (88%) and the foot bones (49%), with multiple fractures often present at diagnosis (76%), and frequently repeated fractures in the patients' recent histories (63%). Diagnosis was conducted using MRI of the painful sites (84%), but bone scintigraphy was also used (41 patients, 45%). Management involved methotrexate discontinuation in 79% of the cases. Fracture healing and pain relief were achieved in 77% of the cases, with a significant difference in outcomes between those who discontinued methotrexate (91%) versus those who continued (29%) (p<0.001). MTX-IO is a rare but significant condition, especially among postmenopausal women with RA or PsA. Early diagnoses via MRI or bone scintigraphy and the discontinuation of methotrexate are critical, as stopping the drug significantly improves outcomes and prevents further fractures.
引用
- Robin F, Ghossan R, Mehsen-Cetre N, et al. METHOFRACT, a methotrexate osteopathy multicentre cohort study. RMD Open. 2025. PMID: 40998522. doi:10.1136/rmdopen-2025-005941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。